ERBB2 and breast carcinoma: Previous studies have demonstrated that HR+HER2+ breast cancers comprised at least luminal A, luminal B and HER2-enriched intrinsic subtypes, and the intrinsic molecular classification was associated with the tumor sensitivity to HER2-targeted therapy 11, 12.